Immunogenicity and immunoprotection of the functional TL-HN fragment derived from tetanus toxin.

Functional domain Immune protection Subunit vaccine TL-HN fragment Tetanus toxin

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
08 Oct 2023
Historique:
received: 18 05 2022
revised: 11 09 2023
accepted: 18 09 2023
medline: 11 10 2023
pubmed: 11 10 2023
entrez: 10 10 2023
Statut: aheadofprint

Résumé

Tetanus toxin (TeNT) is a protein toxin produced by Clostridium tetani bacteria, which causes hyperreflexia and rhabdomyolysis by spastic paralysis. Like botulinum neurotoxin, TeNT comprises a heavy chain (HC) and a light chain (LC) linked via an interchain disulfide bond, which include the following three functional domains: a receptor-binding domain (Hc), a translocation domain (HN), and a catalytic domain (LC). Herein, we produced and characterized three functional domains of TeNT and three types of TeNT-derived L-HN fragments (TL-HN, TL-GS-HN and TL-2A-HN), which contained L and HN domains but lacked the Hc domain. The immunological effects of these different functional domains or fragments of TeNT were explored in an animal model. Our investigations showed the TL-HN functional fragment provided the best immunoprotection among all the TeNT functional domains. The TL-HN fragment, as a protective antigen, induced the highest levels of neutralizing antibodies, indicating that it might contain some crucial epitopes. Further experiments revealed that the protective effect of TL-HN was superior to that of the THc, TL, or THN fragments, either individually or in combination. Therefore, the TL-HN fragment exerts an important function in immune protection against tetanus toxin, providing a good basis for the development of TeNT vaccines or antibodies, and could serve as a promising subunit vaccine to replace THc or tetanus toxoid (TT).

Identifiants

pubmed: 37816654
pii: S0264-410X(23)01102-7
doi: 10.1016/j.vaccine.2023.09.032
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Xu-Yang Liu (XY)

Pharmaceutical College, Henan University, Kaifeng 475001, China; Beijing Institute of Biotechnology, Beijing 100071, China.

Dong-Kui Wei (DK)

Pharmaceutical College, Henan University, Kaifeng 475001, China; Beijing Institute of Biotechnology, Beijing 100071, China.

Zhi-Ying Li (ZY)

Pharmaceutical College, Henan University, Kaifeng 475001, China; Beijing Institute of Biotechnology, Beijing 100071, China.

Jian-Sheng Lu (JS)

Beijing Institute of Biotechnology, Beijing 100071, China.

Xin-Mei Xie (XM)

Pharmaceutical College, Henan University, Kaifeng 475001, China. Electronic address: xxm@vip.henu.edu.cn.

Yun-Zhou Yu (YZ)

Beijing Institute of Biotechnology, Beijing 100071, China. Electronic address: yunzhouyu@163.com.

Xiao-Bin Pang (XB)

Pharmaceutical College, Henan University, Kaifeng 475001, China. Electronic address: pxb0411@163.com.

Classifications MeSH